Neurocrine Biosciences, Inc. Market Research Report

---

Company Overview

• Name: Neurocrine Biosciences, Inc.

• Mission: To relieve suffering for people with great needs but few options, focusing on discovering life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders.

• Founded: In 1992, by Wylie Vale, Ph.D., from the Salk Institute for Biological Studies, and Lawrence Steinman, Ph.D., from Stanford University.

• Key People:

• Kyle W. Gano, Ph.D. - Chief Executive Officer

• Matt Abernethy - Chief Financial Officer

• Eric Benevich - Chief Commercial Officer

• Dimitri E. Grigoriadis, Ph.D. - Distinguished Scholar

• Jude Onyia, Ph.D. - Chief Scientific Officer

• Headquarters: No information is available.

• Number of Employees: More than 1,200.

• Revenue: No information is available.

• Known For: Specializes in the development of treatments for neurological, neuroendocrine, and neuropsychiatric disorders, including FDA-approved treatments for tardive dyskinesia and chorea associated with Huntington's disease.

Products

FDA-Approved Medicines

• Ingrezza® (valbenazine)

• Indications: FDA-approved for tardive dyskinesia and chorea associated with Huntington's disease.

• Key Features: Reduces involuntary movements by inhibiting VMAT2, a protein in the brain that packages neurotransmitters.

Collaboration with AbbVie

• Orilissa® (elagolix tablets)

• Developed in collaboration with AbbVie, launched in the US and Canada in 2018.

• Indications: Treatment of endometriosis.

• Oriahnn® (elagolix, estradiol and norethindrone acetate capsules)

• Launched by AbbVie in the US in 2020.

• Indications: Management of heavy menstrual bleeding due to uterine fibroids.

Investigational Medicines

• Valbenazine (for Huntington's disease)

• NBI-921352 (for epilepsy)

• Crinecerfont (for congenital adrenal hyperplasia)

Recent Developments

• Clinical Studies: Featuring various stages of clinical trials for movement disorders, epilepsy, congenital adrenal hyperplasia, and neuropsychiatric disorders, including:

• KINECT®-HD2 for Huntington's disease (Phase 3)

• KAYAK™ for SCN8A developmental and epileptic encephalopathy (Phase 2)

• CAHtalyst™* for congenital adrenal hyperplasia in pediatric and adult patients (Phase 3)

• Recent Data & Presentations:

• Presented new data at the Psych Congress 2024 demonstrating the efficacy of INGREZZA® across multiple subgroups and improvement in aspects of emotional health.

• Reported Q3 2024 financial results indicating raised expectations for Ingrezza sales guidance.

Recent Partnerships

• Takeda Pharmaceutical Company Limited: Shared profits and losses related to NBI-1065845.

• Mitsubishi Tanabe Pharma Corporation: Commercialization rights for valbenazine in Japan and other select Asian markets.

Pipeline Overview

• Therapeutic Areas: Ongoing R&D in neurology, neuroendocrinology, and neuropsychiatry.

• Purpose: To develop therapies addressing unmet clinical needs, particularly in rare and underserved conditions.

Concluding Note

Neurocrine Biosciences remains committed to bringing innovative treatments to the market, responding to the needs of patients with under-addressed conditions. Through strategic partnerships and a robust pipeline, the company strives to continue its legacy of scientific discovery and therapeutic innovation.